Meimei Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Meimei Yang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Bin Liu
Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
1 shared publication - Chunling Chi
Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin 150001, China
1 shared publication - Chunmei Li
Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin 150001, China
1 shared publication Jing Fang
The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, PR China
1 shared publication- Jinghan Lin
Department of Neurology, First Affiliated Hospital of Harbin Medical University, No.23 Postal Street, Nangang District, Harbin, China
1 shared publication - Liming Zhang
Department of Neurology, The First Affiliated Hospital of Harbin Medical University, 23 Post Street, Harbin 150001, PR China
1 shared publication
Latest Publications
- Open Access
- 1 December 2024
- Vol. 27 (12) , 1506-1514
Genistein inhibits the release of pro-inflammatory substances from macrophages by suppressing potassium loss- and ROS-mediated caspase-1/gasdermin D pathway activation and pyroptotic cell lysis
Objective(s): The expression of pro-inflammatory substances is closely related to various diseases. Genistein (GEN), a soy isoflavone, has been proven to inhibit the production of pro-inflammatory substances in macrophages. This study aimed to determine whether GEN exerts its inhibitory effect on the expression of pro-inflammatory substances by suppressing the release of these substances via attenuating pyroptotic cell lysis. Materials and Methods: Mice were treated with lipopolysaccharide (LPS) and GEN. J774A.1 cells were treated with LPS, adenosine triphosphate (ATP), and GEN. The expression of pro-inflammatory cytokines and high mobility group box 1 (HMGB1) was measured by qRT-PCR and ELISA. The activation of caspase-1 (CASP1) and cleavage of gasdermin D (GSDMD) were determined by Western blot assay. Lactic dehydrogenase (LDH) assay and CCK8 assay were performed to determine the integrity of the cell membrane and cell viability. The concentration of intracellular potassium (K+) and the production of reactive oxygen species (ROS) were determined by the colorimetric method and flow cytometry, respectively. Results: GEN inhibited the production of IL-1 beta and HMGB1 in LPS-challenged mice and LPS+ATP-treated mouse macrophages by inhibiting GSDMD-mediated pyroptotic cell lysis. Mechanistically, GEN could prevent the loss of intracellular K+ and the production of ROS caused by LPS+ATP treatment, thereby inhibiting the activation of CASP1. The pathological significance of the release of HMGB1 could be partially attributed to its ability to induce cell apoptosis. Conclusion: GEN inhibits CASP1/GSDMD-mediated pyroptotic cell lysis and the following release of pro-inflammatory substances by suppressing K+ loss and ROS production of macrophages.
- 1 December 2024
- Vol. 27 (12) , 1506-1514
Open AccessGenistein inhibits the release of pro-inflammatory substances from macrophages by suppressing potassium loss- and ROS-mediated caspase-1/gasdermin D pathway activation and pyroptotic cell lysis
Objective(s): The expression of pro-inflammatory substances is closely related to various diseases. Genistein (GEN), a soy isoflavone, has been proven to inhibit the production of pro-inflammatory substances in macrophages. This study aimed to determine whether GEN exerts its inhibitory effect on the expression of pro-inflammatory substances by suppressing the release of these substances via attenuating pyroptotic cell lysis. Materials and Methods: Mice were treated with lipopolysaccharide (LPS) and GEN. J774A.1 cells were treated with LPS, adenosine triphosphate (ATP), and GEN. The expression of pro-inflammatory cytokines and high mobility group box 1 (HMGB1) was measured by qRT-PCR and ELISA. The activation of caspase-1 (CASP1) and cleavage of gasdermin D (GSDMD) were determined by Western blot assay. Lactic dehydrogenase (LDH) assay and CCK8 assay were performed to determine the integrity of the cell membrane and cell viability. The concentration of intracellular potassium (K+) and the production of reactive oxygen species (ROS) were determined by the colorimetric method and flow cytometry, respectively. Results: GEN inhibited the production of IL-1 beta and HMGB1 in LPS-challenged mice and LPS+ATP-treated mouse macrophages by inhibiting GSDMD-mediated pyroptotic cell lysis. Mechanistically, GEN could prevent the loss of intracellular K+ and the production of ROS caused by LPS+ATP treatment, thereby inhibiting the activation of CASP1. The pathological significance of the release of HMGB1 could be partially attributed to its ability to induce cell apoptosis. Conclusion: GEN inhibits CASP1/GSDMD-mediated pyroptotic cell lysis and the following release of pro-inflammatory substances by suppressing K+ loss and ROS production of macrophages.
- Open Access
- 14 April 2023
- Published by Hindawi Limited in Parkinson's Disease
- Vol. 2023, 1-17
Identification of Hub Genes and Potential Molecular Pathogenesis in Substantia Nigra in Parkinson’s Disease via Bioinformatics Analysis
Parkinson’s disease (PD) is the second most common neurodegenerative disease, with significant socioeconomic burdens. One of the crucial pathological features of PD is the loss of dopaminergic neurons in the substantia nigra (SN). However, the exact pathogenesis remains unknown. Moreover, therapies to prevent neurodegenerative progress are still being explored. We performed bioinformatics analysis to identify candidate genes and molecular pathogenesis in the SN of patients with PD. We analyzed the expression profiles, GSE49036 and GSE7621, which included 31 SN tissues in P D s a m p l e s a n d 17 SN tissues in healthy control samples, and identified 86 common differentially expressed genes (DEGs). Then, GO and KEGG pathway analyses of the identified DEGs were performed to understand the biological processes and significant pathways of PD. Subsequently, a protein-protein interaction network was established, with 15 hub genes and four key modules which were screened in this network. The expression profiles, GSE8397 and GSE42966, were used to verify these hub genes. We demonstrated a decrease in the expression levels of 14 hub genes in the SN tissues of PD samples. Our results indicated that, among the 14 hub genes, DRD2, SLC18A2, and SLC6A3 may participate in the pathogenesis of PD by influencing the function of the dopaminergic synapse. CACNA1E, KCNJ6, and KCNB1 may affect the function of the dopaminergic synapse by regulating ion transmembrane transport. Moreover, we identified eight microRNAs (miRNAs) that can regulate the hub genes and 339 transcription factors (TFs) targeting these hub genes and miRNAs. Subsequently, we established an mTF-miRNA-gene-gTF regulatory network. Together, the identification of DEGs, hub genes, miRNAs, and TFs could provide better insights into the pathogenesis of PD and contribute to the diagnosis and therapies.
- 14 April 2023
- Published by Hindawi Limited in Parkinson's Disease
- Vol. 2023, 1-17
Open AccessIdentification of Hub Genes and Potential Molecular Pathogenesis in Substantia Nigra in Parkinson’s Disease via Bioinformatics Analysis
Parkinson’s disease (PD) is the second most common neurodegenerative disease, with significant socioeconomic burdens. One of the crucial pathological features of PD is the loss of dopaminergic neurons in the substantia nigra (SN). However, the exact pathogenesis remains unknown. Moreover, therapies to prevent neurodegenerative progress are still being explored. We performed bioinformatics analysis to identify candidate genes and molecular pathogenesis in the SN of patients with PD. We analyzed the expression profiles, GSE49036 and GSE7621, which included 31 SN tissues in P D s a m p l e s a n d 17 SN tissues in healthy control samples, and identified 86 common differentially expressed genes (DEGs). Then, GO and KEGG pathway analyses of the identified DEGs were performed to understand the biological processes and significant pathways of PD. Subsequently, a protein-protein interaction network was established, with 15 hub genes and four key modules which were screened in this network. The expression profiles, GSE8397 and GSE42966, were used to verify these hub genes. We demonstrated a decrease in the expression levels of 14 hub genes in the SN tissues of PD samples. Our results indicated that, among the 14 hub genes, DRD2, SLC18A2, and SLC6A3 may participate in the pathogenesis of PD by influencing the function of the dopaminergic synapse. CACNA1E, KCNJ6, and KCNB1 may affect the function of the dopaminergic synapse by regulating ion transmembrane transport. Moreover, we identified eight microRNAs (miRNAs) that can regulate the hub genes and 339 transcription factors (TFs) targeting these hub genes and miRNAs. Subsequently, we established an mTF-miRNA-gene-gTF regulatory network. Together, the identification of DEGs, hub genes, miRNAs, and TFs could provide better insights into the pathogenesis of PD and contribute to the diagnosis and therapies.
- 1 December 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 494 (3-4) , 526-533
Role of ROS-TRPM7-ERK1/2 axis in high concentration glucose-mediated proliferation and phenotype switching of rat aortic vascular smooth muscle cells
- 1 December 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 494 (3-4) , 526-533
Role of ROS-TRPM7-ERK1/2 axis in high concentration glucose-mediated proliferation and phenotype switching of rat aortic vascular smooth muscle cells